- Home
- NMCO vs CRMD Comparison
NMCO vs CRMD Comparison
Compare NMCO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- CRMD
- Stock Information
- Founded
- NMCO 2019
- CRMD 2006
- Country
- NMCO United States
- CRMD United States
- Employees
- NMCO N/A
- CRMD N/A
- Industry
- NMCO Finance/Investors Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- CRMD Health Care
- Exchange
- NMCO Nasdaq
- CRMD Nasdaq
- Market Cap
- NMCO 577.1M
- CRMD 973.3M
- IPO Year
- NMCO N/A
- CRMD 2010
- Fundamental
- Price
- NMCO $10.83
- CRMD $11.88
- Analyst Decision
- NMCO
- CRMD Strong Buy
- Analyst Count
- NMCO 0
- CRMD 7
- Target Price
- NMCO N/A
- CRMD $17.33
- AVG Volume (30 Days)
- NMCO 207.6K
- CRMD 2.4M
- Earning Date
- NMCO 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- NMCO 5.43%
- CRMD N/A
- EPS Growth
- NMCO N/A
- CRMD N/A
- EPS
- NMCO N/A
- CRMD 0.28
- Revenue
- NMCO N/A
- CRMD $82,553,827.00
- Revenue This Year
- NMCO N/A
- CRMD $238.38
- Revenue Next Year
- NMCO N/A
- CRMD $53.52
- P/E Ratio
- NMCO N/A
- CRMD $42.69
- Revenue Growth
- NMCO N/A
- CRMD N/A
- 52 Week Low
- NMCO $8.52
- CRMD $3.61
- 52 Week High
- NMCO $11.64
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- NMCO 71.10
- CRMD 41.24
- Support Level
- NMCO $10.46
- CRMD $12.14
- Resistance Level
- NMCO $10.58
- CRMD $17.43
- Average True Range (ATR)
- NMCO 0.13
- CRMD 0.75
- MACD
- NMCO 0.03
- CRMD -0.42
- Stochastic Oscillator
- NMCO 87.50
- CRMD 0.55
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.